DSGN - Design Therapeutics Inc Company Long-Term Indebtedness

Brandmark of Design Therapeutics Inc (DSGN)

Design Therapeutics develops unique drugs to correct genetic defects, providing the company with market advantages in the therapy of rare pathologies. Design Therapeutics is expanding its scientific potential through alliances with laboratories, increasing its attractiveness for future acquisitions. Management is currently revising trial protocols to confirm molecular safety, while long-term debt stands at 0.00. This price chart on GURU.Markets visualizes the impact of these factors on capitalization.

Design Therapeutics, Inc. (DSGN) Company Long-Term Debt: for the period 07/04/2022 - 10/29/2026

Design Pharma (DSGN) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price designtx.com|DSGN - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Design Therapeutics|DSGN - Enterprise Value
- balance sheet net asset value indicators:
Net Asset Value per Share Design Therapeutics|DSGN - Company Book Value|Market Capitalization to Book Value designtx.com|DSGN - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Coefficient Design Therapeutics|DSGN - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Design Corp|DSGN - Company Debts|Debt to Book Value Ratio Design Therapeutics|DSGN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Design Therapeutics
Analysis of all company metrics:designtx.com - DSGN
Signature product of Design Pharma

Professional capital assesses the profile of Design Therapeutics (DSGN) through a liability structure with a maturity horizon of over one year. This indicator measures the volume of long-term loans, transforming quarterly data into a continuous stream of credit risk probabilities. By analyzing the trend of the business's long-term debt capital, the investor identifies a resource for scaling amidst sanction pressure on biotechnology. The stability of this metric confirms the financial resilience of Design Therapeutics (DSGN) during a slowdown in global research.

Competitor analysis for Design Therapeutics

Company Long-Term Debts Tempus Labs TEM|Qiagen - Company Long-Term Debts|IONS (Ionis Pharmaceuticals, Inc.) - Company Long-Term Indebtedness|RGEN: Company Long-Term Debts|Long-Term Debt Avidity Corp (RNA)|Company Long-Term Debt CRISPR Therapeutics AG|genedx.com (WGS) - Long-Term Debt Volume|Company Long-Term Debts RARE|Long-Term Debt Volume Beam Therapeutics Inc|Company Long-Term Debts SRPT (Sarepta Therapeutics Inc)|Long-Term Indebtedness Twist Bioscience Corp|TXG - Company Long-Term Debt|NTLA (intelliatx.com) - Company Long-Term Indebtedness|STOK (Stoke Therapeutics, Inc.) - Company Long-Term Liabilities|BioLife Solutions Inc - Company Long-Term Loans and Borrowings|Company Long-Term Liabilities WVE|MAZE (Maze Therapeutics Corp) - Amount of Long-Term Liabilities|Company Long-Term Debts SION|PRME (primemedicine.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts TSHA (Taysha Gene Therapies, Inc.)|uniQure NV (QURE) - Long-Term Debt|MGTX - Company Long-Term Debt|Company Long-Term Loans and Borrowings RGNX (REGENXBIO Corp)|SLDB: Company Long-Term Debts|ocugen.com (OCGN) - Company Long-Term Debts|Company Long-Term Debt PacBio|Benitec Biopharma Inc - Long-Term Liabilities|Company Long-Term Debts RCKT|FDMT - Long-Term Debt|Lexeo Therapeutics, Inc. - Company Long-Term Liabilities|Company Long-Term Debts Korro Bio Inc. KRRO|EDIT: Company Long-Term Liabilities|Silence Therapeutics PLC - Amount of Long-Term Liabilities|PRQR: Company Long-Term Debts|CDXS - Long-Term Debt Volume|SGMO (Sangamo Therapeutics) - Company Long-Term Debts|Company Long-Term Liabilities Nautilus Biotechnology Inc (NAUT)|Company Long-Term Debt Metagenomi (MGX)|Long-Term Debt Volume Precision BioSciences Inc.|Company Long-Term Debts GBIO (Generation Bio)|BOLD: Company Long-Term Indebtedness|XCUR - Company Long-Term Debt|Long-Term Debt Volume Imunon, Inc. IMNN|PHIO: Company Long-Term Debts|Long-Term Indebtedness Mustang Bio MBIO|Company Long-Term Debt TransCode Therapeutics Inc.|Company Long-Term Indebtedness BNGO (Bionano)|Company Long-Term Debts APDN|bluebirdbio.com - Company Long-Term Indebtedness|Company Long-Term Debt ImmunoPrecise Antibodies Ltd. IPA|OMGA: Company Long-Term Indebtedness|Singular Genomics Systems Inc - Company Long-Term Debts|RGLS - Company Long-Term Debts|SYRS: Company Long-Term Debts|Company Long-Term Indebtedness TBIO|TCON (TRACON Pharmaceuticals, Inc.) - Company Long-Term Debts|Long-Term Debt Unity Biotechnology Inc. UBX